- Home
- BEAM vs MYGN Comparison
BEAM vs MYGN Comparison
Compare BEAM & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- MYGN
- Stock Information
- Founded
- BEAM 2017
- MYGN 1991
- Country
- BEAM United States
- MYGN United States
- Employees
- BEAM N/A
- MYGN N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BEAM Health Care
- MYGN Health Care
- Exchange
- BEAM Nasdaq
- MYGN Nasdaq
- Market Cap
- BEAM 1.6B
- MYGN 744.7M
- IPO Year
- BEAM 2020
- MYGN 1995
- Fundamental
- Price
- BEAM $21.16
- MYGN $5.34
- Analyst Decision
- BEAM Strong Buy
- MYGN Hold
- Analyst Count
- BEAM 11
- MYGN 15
- Target Price
- BEAM $48.90
- MYGN $15.14
- AVG Volume (30 Days)
- BEAM 2.2M
- MYGN 1.3M
- Earning Date
- BEAM 08-05-2025
- MYGN 08-05-2025
- Dividend Yield
- BEAM N/A
- MYGN N/A
- EPS Growth
- BEAM N/A
- MYGN N/A
- EPS
- BEAM N/A
- MYGN N/A
- Revenue
- BEAM $63,578,000.00
- MYGN $831,300,000.00
- Revenue This Year
- BEAM N/A
- MYGN N/A
- Revenue Next Year
- BEAM $17.18
- MYGN $6.68
- P/E Ratio
- BEAM N/A
- MYGN N/A
- Revenue Growth
- BEAM N/A
- MYGN 7.38
- 52 Week Low
- BEAM $13.53
- MYGN $3.81
- 52 Week High
- BEAM $35.25
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- BEAM 65.49
- MYGN 50.85
- Support Level
- BEAM $19.02
- MYGN $4.90
- Resistance Level
- BEAM $22.51
- MYGN $5.83
- Average True Range (ATR)
- BEAM 1.15
- MYGN 0.28
- MACD
- BEAM 0.49
- MYGN 0.04
- Stochastic Oscillator
- BEAM 78.91
- MYGN 54.21
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.